viewPreveCeutical Medical Inc.

PreveCeutical completes efficacy screening of small interfering RNA-based therapy for type 2 diabetes

The treatment targets a specific gene of interest responsible for the overproduction of a protein molecule that causes diabetes and obesity

siRNA bound to mRNA
The company identified siRNA constructs and chemically transformed them into “smart siRNAs” that work to turn off the gene of interest

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) has completed efficacy screening of its small interfering RNA (siRNA) gene silencing therapy as a treatment for type 2 diabetes and obesity. 

The treatment works by targeting a specific gene of interest responsible for the overproduction of a protein molecule that has been identified as responsible for causing diabetes and obesity.

Earlier this year, the company identified a panel of siRNA constructs and worked to chemically transform them into what it calls “smart siRNAs” that work to essentially turn off the gene of interest.

READ: PreveCeutical makes good progress with non-addictive painkiller research program

On Monday, PreveCeutical announced that it has completed screening of its smart siRNAs. The company found that smart siRNA’s gene silencing potency was retained and comparable to that of the original siRNAs, meaning the chemical modifications made by the company did not reduce efficacy.

"We are pleased with the latest Smart-siRNA screening results, which show a great promise in retention of the siRNA's stability and no apparent changes in their potency. We look forward to further progressing our dual gene therapy research program."

Biostability is essential for the company as it looks ahead towards assessment in preclinical mice models of type 2 diabetes and obesity.

PreveCeutical stock held flat at $C0.03 on the CSE on Monday and jumped 19% to nearly US$0.03 on OTC Markets.

—Updated to include stock movement—

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: PreveCeutical Medical Inc.

Price: 0.08 CAD

Market: CSE
Market Cap: $31.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...



Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 11/15/2019

2 min read